Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

ShardaCare-Healthcity launches Greater Noida’s first comprehensive cancer care centre

Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof

New genomics clinic by Fortis Hospitals targets early disease detection

New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

ModeX doses first patients in trial of next-gen T-cell engager for aggressive B-cell lymphoma

The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack

AbbVie bets $1.4B on North Carolina pharma mega-campus

Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev